3032 related articles for article (PubMed ID: 32152082)
21. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
de Wit E; Feldmann F; Cronin J; Jordan R; Okumura A; Thomas T; Scott D; Cihlar T; Feldmann H
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6771-6776. PubMed ID: 32054787
[TBL] [Abstract][Full Text] [Related]
23. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
24. Psychopharmacology of COVID-19.
Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL
Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246
[TBL] [Abstract][Full Text] [Related]
25. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Magro G
Virus Res; 2020 Sep; 286():198070. PubMed ID: 32569708
[TBL] [Abstract][Full Text] [Related]
26. More than 80 clinical trials launch to test coronavirus treatments.
Maxmen A
Nature; 2020 Feb; 578(7795):347-348. PubMed ID: 32071447
[No Abstract] [Full Text] [Related]
27. Potential strategies for combating COVID-19.
Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
[TBL] [Abstract][Full Text] [Related]
28. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
29. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
[TBL] [Abstract][Full Text] [Related]
30. Race to find COVID-19 treatments accelerates.
Kupferschmidt K; Cohen J
Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
[No Abstract] [Full Text] [Related]
31. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
[No Abstract] [Full Text] [Related]
32. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
[TBL] [Abstract][Full Text] [Related]
33. Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection.
Li C; Wang L; Ren L
Virus Res; 2020 Sep; 286():198073. PubMed ID: 32592817
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
35. [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Estella Á; Garnacho-Montero J
Med Intensiva (Engl Ed); 2020 Nov; 44(8):509-512. PubMed ID: 32423569
[No Abstract] [Full Text] [Related]
36. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Li H; Liu Z; Ge J
J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
[TBL] [Abstract][Full Text] [Related]
37. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
[TBL] [Abstract][Full Text] [Related]
38. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
39. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
Liang C; Tian L; Liu Y; Hui N; Qiao G; Li H; Shi Z; Tang Y; Zhang D; Xie X; Zhao X
Eur J Med Chem; 2020 Sep; 201():112527. PubMed ID: 32563812
[TBL] [Abstract][Full Text] [Related]
40. [Chloroquine as a possible treatment for COVID-19].
Coumou J; de Vries PJ
Ned Tijdschr Geneeskd; 2020 Mar; 164():. PubMed ID: 32391999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
